- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- Today's Market Action
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Israel Going Green
- China's Role as Lender Alters Dynamics for United States
- Inside Wal-Mart's Acai Berry Juice Maker
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Low Interest Rate Investing
Text Size 
Baxter [BAX
Loading...
()
] researchers revealed positive mid-stage test results on an intravenous drug, Gammagard, that's already in late-stage development in a very small number of patients.
According to test reports, the plasma-based drug appears to improve memory and quality of life—or at the very least, stabilize and stop the rate of loss of memory.
Baxter's stock rose almost 2 percent when the data was released. (See the accompanying video for more.)
Meanwhile, Elan [ELN
Loading...
()
] and Wyeth’s [WYE
Loading...
()
] shares plunged Wednesday after word that mid-stage test results on a potentially first-of-its-kind Alzheimer’s drug, Bapineuzumab, raised safety issues.
However, Elan CEO Kelly Martin told CNBC he was confident in Bapineuzumab.
"There are obviously some gaps between the market interpretation and what we know,” Martin said.
Additionally, a small biofirm, Medivation [MDVN
Loading...
()
], showed new data on an anti-histamine that in a large study appears to preserve memory in mild to moderate Alzheimer’s patients.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes